13:47:43 EST Fri 14 Feb 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:PHIO - PHIO PHARMACEUTICALS CORP - https://phiopharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHIO - Q0.11.80·1.810.11.8101+0.02011.1186.33043731.83  1.88  1.7910.35  1.5313:23:25Feb 0315 min RT 2¢

Recent Trades - Last 10 of 373
Time ETExPriceChangeVolume
13:23:25Q1.810.02200
13:23:25Q1.810.02500
13:23:25Q1.81010.0201200
13:23:25Q1.81010.0201500
13:23:25Q1.81010.02013,300
13:21:53Q1.810.0213
13:16:23Q1.81960.029627
13:16:23Q1.81930.02931
13:16:23Q1.81960.02961
13:12:43Q1.81950.0295200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-02-03 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-01-22 07:02U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-01-21 16:16U:PHIONews ReleasePhio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-16 13:01U:PHIONews ReleasePhio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-15 07:01U:PHIONews ReleasePhio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-14 07:01U:PHIONews ReleasePhio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-13 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
2025-01-02 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
2024-12-23 13:16U:PHIONews ReleasePhio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-12-19 14:29U:PHIONews ReleasePhio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-12-19 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
2024-12-12 09:22U:PHIONews ReleasePhio Pharmaceuticals Announces Publication in Frontiers in Immunology
2024-12-10 07:46U:PHIONews ReleasePhio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
2024-12-03 07:46U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-11-19 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
2024-11-14 17:48U:PHIONews ReleasePhio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-07 10:01U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-11-01 07:47U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-10-24 08:02U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-10-18 13:31U:PHIONews ReleaseCorrection to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series